These results agree with the reports that showed positive effects of mGluR5 inhibitors on abnormalities in prepulse inhibition (PPI) in FXS patients (Berry-Kravis et al. 2009) and Fmr1 KO mice (de Vrij et al. 2008). This evidence concerns the gene GRM5 and fragile X syndrome.